We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+7.47%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$12.3B
AUM Growth
+$1.06B
Cap. Flow
+$761M
Cap. Flow %
6.18%
Top 10 Hldgs %
58.32%
Holding
100
New
18
Increased
36
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
AET
Aetna Inc
AET
+$896M
2
COL
Rockwell Collins
COL
+$339M
3
MON
Monsanto Co
MON
+$161M
4
ELV icon
Elevance Health
ELV
+$131M
5
CHTR icon
Charter Communications
CHTR
+$92.5M

Top Sells

Rank Stock Value
1
BCR
CR Bard Inc.
BCR
+$508M
2
TWX
Time Warner Inc
TWX
+$393M
3
HDS
HD Supply Holdings, Inc.
HDS
+$196M
4
KITE
Kite Pharma, Inc.
KITE
+$175M
5
ALR
Alere Inc
ALR
+$138M

Sector Composition

Rank Sector Weight
1 Technology 22.48%
2 Healthcare 15.61%
3 Communication Services 13.96%
4 Financials 11.79%
5 Industrials 9.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EFX icon
26
Equifax
EFX
$22.6B
$153M 1.24%
1,299,175
+9,175
+0.7% +$1.03M
LBTYK icon
27
Liberty Global Class C
LBTYK
$3.55B
$139M 1.13%
4,102,123
+1,012,350
+33% +$31.1M
AZN icon
28
AstraZeneca
AZN
$257B
$131M 1.06%
1,882,500
+292,500
+18% +$19.7M
RDUS
29
DELISTED
Radius Health, Inc.
RDUS
$125M 1.02%
3,936,300
– –
LBTYA icon
30
Liberty Global Class A
LBTYA
$3.63B
$117M 0.95%
3,270,180
+277,245
+9% +$8.81M
VEON icon
31
VEON
VEON
$4.09B
$113M 0.92%
1,177,341
– –
HUN icon
32
Huntsman Corp
HUN
$1.75B
$80.7M 0.66%
2,425,000
-1,075,000
-31% -$32.9M
KYNB
33
Kyntra Bio
KYNB
$30.4M
$78.6M 0.64%
66,300
+22,300
+51% +$28M
BMY icon
34
Bristol-Myers Squibb
BMY
$137B
$73.1M 0.59%
1,192,500
-162,500
-12% -$10.2M
AKRX
35
DELISTED
Akorn Inc
AKRX
$72.6M 0.59%
2,251,300
-28,700
-1% -$941K
ABBV icon
36
AbbVie
ABBV
$468B
$67.7M 0.55%
700,000
+115,000
+20% +$10.8M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$65.9M 0.54%
400,000
+156,500
+64% +$15.2M
GNCMA
38
DELISTED
GCI Liberty, Inc. Class A-1 Common Stock
GNCMA
$64.1M 0.52%
1,643,800
– –
ABLX
39
DELISTED
Ablynx NV
ABLX
$58.7M 0.48%
+2,350,000
New +$53.1M
ANAB icon
40
AnaptysBio
ANAB
$1.71B
$56.5M 0.46%
561,000
+315,000
+128% +$23.2M
ENTA icon
41
Enanta Pharmaceuticals
ENTA
$392M
$54.3M 0.44%
925,000
+512,667
+124% +$25.7M
QCOM icon
42
Qualcomm
QCOM
$169B
$50.6M 0.41%
789,783
+704,783
+829% +$42.7M
XLRN
43
DELISTED
Acceleron Pharma
XLRN
$46.2M 0.38%
1,088,000
+125,000
+13% +$4.69M
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
$40M 0.33%
2,781,000
-2,300,055
-45% -$31.6M
MYOK
45
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$36.4M 0.3%
863,732
+466,232
+117% +$18M
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
$34M 0.28%
850,000
+530,000
+166% +$20.4M
RC
47
Ready Capital
RC
$311M
$33.3M 0.27%
2,200,007
-124,229
-5% -$1.95M
SVRA icon
48
Savara
SVRA
$1.15B
$33M 0.27%
2,225,000
– –
IONS icon
49
Ionis Pharmaceuticals
IONS
$9.93B
$32.4M 0.26%
645,000
+195,000
+43% +$10.7M
GRFS
50
Grifois
GRFS
$5.44B
$32.3M 0.26%
1,408,760
-21,013
-1% -$467K
1
2
3 4

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2017 Portfolio in Review

As of Q4 2017, Thomas Steyer held 100 positions worth $12.3B, up 9.4% from $11.3B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Thomas Steyer deployed $761M of net new capital in Q4 2017, opening 18 new positions and adding to 36 existing holdings. Its largest new stake was Aetna Inc: 5,215,000 shares worth $941M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Time Warner Inc, an estimated $393M trimmed.

  • Thomas Steyer's largest Q4 2017 buy was Aetna Inc: 5,215,000 shares worth $941M.
  • Thomas Steyer added most to Monsanto Co in Q4 2017, an estimated $161M increase.
  • Thomas Steyer's biggest Q4 2017 reduction was Time Warner Inc, cutting an estimated $393M.
  • Thomas Steyer fully exited CR Bard Inc. in Q4 2017, selling an estimated $508M.
  • Thomas Steyer's ten largest holdings make up 58% of its $12.3B portfolio in Q4 2017.
  • Thomas Steyer opened 18 new positions and closed 19 in Q4 2017.
  • Thomas Steyer's portfolio value rose 9.4% quarter-over-quarter to $12.3B.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.